For example, sub-analysis of Black and White women with HR+/HER2-breast cancer enrolled in a clinical trial comparing the efficacy of different taxane regimens revealed significantly worse disease-free (HR 1.58, 95% CI 1.19–2.10), overall (HR 1.49, 95% CI 1.05–2.02) and BCSS (HR 1.65, 95% CI 1.11–2.46) in Black women [13]. This evidence concerns the gene ERBB2 and breast carcinoma.